论文部分内容阅读
本文评价服用格列齐特缓释片 (达美康缓释剂 30 mg片剂 )治疗 12周后 ,2型糖尿病患者血糖总体控制的有效性及安全性 ,并与普通剂型比较。研究中将 15 9例 2型糖尿病患者随机分配到格列齐特缓释剂组和普通剂型组进行治疗。治疗 12周后以血糖化血红蛋白 ,空腹血浆葡萄糖和胰岛素
This review evaluates the overall efficacy and safety of glycemic control in patients with type 2 diabetes mellitus after 12 weeks of treatment with gliclazide extended-release tablets (up to 25 mg of sustained-release tablets). Fifteen ninety-two patients with type 2 diabetes were randomized to Gliclazide and normal-dosage forms for treatment. After 12 weeks of treatment with glycosylated hemoglobin, fasting plasma glucose and insulin